Lexaria (NASDAQ: LEXX) Announces Availability of “The Power of Science to Stop a Killer”

August 31, 2022 10:21:58
  • Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point
  • Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment
  • Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose side effects far outweigh their benefits
  • The company looks to capitalize on the growing global anti-hypertensive drugs market, which is projected to hit $27.81 billion in value by 2025, and maintains that should it sustain the results achieved in recent hypertension studies, then it could be looking at mega-drug status ($1 billion per year) in the hypertension market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its latest addition to a growing body of corporate communication pieces in its line-up. Titled “The Power of Science to Stop a Killer,” this recent broadcast highlights the company’s progress in finding a potential solution for hypertension treatment, while also pointing out why a solution is much needed at this point (https://cnw.fm/6E6Dy).

Lexaria’s flagship offering, its patented DehydraTECH(TM) technology, has proven to improve ways through which active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.